S416

S416

Identifiers
IUPAC name 2-[(E)-[[4-(2-chlorophenyl)-1,3-thiazol-2-yl]-methylhydrazinylidene}]methyl]benzoic acid
CAS Number	2118370-02-6  Y
PubChem CID	148568163
CompTox Dashboard (EPA)	DTXSID901337017
Chemical and physical data
Formula	C18H14ClN3O2S
Molar mass	371.84 g·mol−1
3D model (JSmol)	Interactive image
SMILES CN(C1=NC(=CS1)C2=CC=CC=C2Cl)/N=C\C3=CC=CC=C3C(=O)O
InChI InChI=1S/C18H14ClN3O2S/c1-22(20-10-12-6-2-3-7-13(12)17(23)24)18-21-16(11-25-18)14-8-4-5-9-15(14)19/h2-11H,1H3,(H,23,24)/b20-10- Key:MWIQPUXVXAVFRM-JMIUGGIZSA-N

S416 (GTPL-11164) is a drug which acts as a selective inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH). This enzyme is involved in the synthesis of pyrimidine nucleosides in the body, which are required for the synthesis of DNA and RNA. This is an important rate-limiting step in the replication of viruses, and so DHODH inhibitors may have applications as broad-spectrum antiviral drugs. In tests in vitro, S416 was found to have antiviral activity against a range of pathogenic RNA viruses including influenza, Zika virus, Ebola virus and SARS-CoV-2. ^{[1] [2]}

See also

• Brequinar
• Teriflunomide
• Leflunomide

References

1. Xiong R, Zhang L, Li S, Sun Y, Ding M, Wang Y, et al. (October 2020). "Novel and potent inhibitors targeting DHODH are broad-spectrum antivirals against RNA viruses including newly-emerged coronavirus SARS-CoV-2". Protein & Cell. 11 (10): 723–739. doi:10.1007/s13238-020-00768-w. PMC   7402641 . PMID   32754890.
2. Tian D, Liu Y, Liang C, Xin L, Xie X, Zhang D, et al. (May 2021). "An update review of emerging small-molecule therapeutic options for COVID-19". Biomedicine & Pharmacotherapy. 137 111313. doi:10.1016/j.biopha.2021.111313. PMC   7857046 . PMID   33556871.